Safety, immunogenicity and risk –benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

Future Microbiology, Ahead of Print.

Source: Future Microbiology - February 6, 2020 Category: Microbiology Authors: Bache Emmanuel Bache Martin P Grobusch Selidji Todagbe Agnandji Source Type: research